GTBP•benzinga•
EXCLUSIVE: GT Biopharma Advances Relapsed Blood Cancer Therapy Trial To Cohort 2 After Promising Early Safety Results
Summary
GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing potential for NK cell expansion and increased immunologic activity. Detailed results to be released in 2025. GTBP stock up 0.90%.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 19, 2025 by benzinga